Efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C

Efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C - EBR/GZR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025050

Enrollment

500

Registered

2016-11-29

Start date

2016-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic hepatitis C virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with 20 years of age and older 2) Chronic hepatitis or compensated cirrhosis patients with HCV serogroup 1 3) Eligible patients for elbasvir and grazoprevir

Exclusion criteria

Exclusion criteria: 1) Contraindication to elbasvir or grazoprevir 2) Contraindication to elbasvir and grazoprevir

Design outcomes

Primary

Measure	Time frame
Sustained virologic response rate Safety Cumulative incidence of hepatocellular carcinoma	—

Secondary

Measure	Time frame
The factor associated with sustained virologic response Emergence of drug-resistant virus The factor associated with incidence of hepatocellular carcinoma	—

Countries

Japan

Contacts

Public ContactYuki Tahata

Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology

yuki.tahata@gh.med.osaka-u.ac.jp+81-6-6879-3621

Outcome results